Glucosamine/chondroitin use significantly associated with lo
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Regular intake of glucosamine/chondroitin was associated with lower all-cause and CVD mortality among adults aged older than 40 years in the United States, data from a cohort study showed.

Limited previous studies in the United Kingdom or a single US state have demonstrated an association between intake of glucosamine/chondroitin and mortality. This study sought to investigate the association between regular consumption of glucosamine/chondroitin and overall and cardiovascular (CVD) mortality in a national sample of US adults.

Combined data from 16,686 participants in National Health and Nutrition Examination Survey 1999 to 2010, merged with the 2015 Public-use Linked Mortality File. Cox proportional hazards models were conducted for both CVD and all-cause mortality.

Results:
-- In the study sample, there were 658 (3.94%) participants who had been taking glucosamine/chondroitin for a year or longer.

-- During followup (median, 107 months), there were 3366 total deaths (20.17%); 674 (20.02%) were due to CVD.

-- Respondents taking glucosamine/chondroitin were less likely to have CVD mortality.

-- After controlling for age, use was associated with a 39% reduction in all-cause and 65% reduction in CVD mortality.

-- Multivariable-adjusted HR showed that the association was maintained after adjustment for age, sex, race, education, smoking status, and physical activity.

Conclusively, regular intake of glucosamine/chondroitin is associated with lower all-cause and CVD mortality in a national US cohort and the findings are consistent with previous studies in other populations. Prospective studies to confirm the link may be warranted.

Source: https://www.jabfm.org/content/33/6/842
Like
Comment
Share